

# MODULE 1: What You Can't Feel Can Hurt You

David Herrmann, MD & Alicia Gotcsik, CO, CPED

## Program Description

This module includes a discussion of the clinical features and diagnosis of diabetic distal symmetrical polyneuropathy (DSN). The consideration of the differential diagnosis of DSPN, the appropriate work-up and management options will be covered. The second speaker will explain the mechanisms of injury/symptoms of complications of the neuropathic foot in the setting of ulceration, Charcot Arthropathy and amputation. Orthotic treatment protocols for the insensate foot including diabetic wounds, Charcot Arthropathy and partial foot amputations will be reviewed.

## Learning Objectives

*At the conclusion of this activity, participants should be able to:*

- Diagnose diabetic distal symmetric polyneuropathy (DSPN) and differentiate it from other forms of diabetic neuropathy and other causes of distal symmetric polyneuropathy.
- Learn about management options for DSPN and treatment outcomes.
- Have a better understanding of treatment protocols for complications of the diabetic foot.
- Help understand the mechanisms of injury of the insensate foot/ offer prevention tips to patients.

## Bibliographic Sources to Allow for Further Study

- Pop-Busui, R et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. *Diabetes Care* 2017;40:136–154.
- Callaghan BC et al. Diabetes and obesity are the main metabolic drivers of peripheral neuropathy. *Annals of Clinical and Translational Neurology* 2018; 5(4): 397–405.
- American Orthopaedic Foot/Ankle Society: Diabetic Foot Overview. [http://legacy.aofas.org/footcaremd/conditions/diabetic foot](http://legacy.aofas.org/footcaremd/conditions/diabetic%20foot).
- American Diabetes Association: The Charcot Foot in Diabetes. <http://care.diabetesjournals.org>.

## Accreditation

The University of Rochester School of Medicine and Dentistry is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

## Certification

The University of Rochester School of Medicine and Dentistry designates this enduring material for a maximum of 1.0 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

***No commercial funds have been received to support this educational activity.***

## Planning Committee / Speaker Disclosures

The following speakers have disclosed financial interests/arrangements or affiliations with organization(s) that could be perceived as a real or apparent conflict of interest in the context of the subject of their presentation(s). Only the current arrangements/interests are included.

\*Planning Committee Members

Tamara Eis, MS, RN-BC\*

Alicia Gotcsik, CO, CPED

Stephen Hammes, MD, PhD\*

David Herrmann, MD

Heidi Kipp, NP\*

Steven Wittlin, MD\*

Planner declared that no financial interest or relationship exists

Speaker declared that no financial interest or relationship exists

Planner declared that no financial interest or relationship exists

Speaker declared Consultant for Regenacy (Scientific Advisory Board)

Planner declared that no financial interest or relationship exists

Planner declared Consultant for Sensionics and Speakers' Bureau for Medtronic Diabetes

The Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support require that presentations are free of commercial bias and that any information regarding commercial products/services be based on scientific methods generally accepted by the medical community. When discussing therapeutic options, speakers are requested to use only generic names. If they use a trade name, then those of several companies should be used. If a presentation includes discussion of any unlabeled or investigational use of a commercial product, speakers are required to disclose this to the participants.